



## Oncologist's Corner: Conversations with Cancer Experts About Novel Delivery Options with Immune Checkpoint Inhibitors



### Reference List

- Albiges L, Bournon MT, Chacón M, et al. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. *Ann Oncol*. 2024;S0923-7534(24)03996-6. doi:10.1016/j.annonc.2024.09.002
- Burotto M, Zvirbule Z, Mochalova A, et al. IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. *Ann Oncol*. 2023;34(8):693-702. doi:10.1016/j.annonc.2023.05.009
- Boudreau A. Practical considerations for the integration of subcutaneous targeted therapies into the oncology clinic. *Can Oncol Nurs J*. 2019;29(4):267-270.
- Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. *Lancet*. 2021;398(10304):1002-1014. doi:10.1016/S0140-6736(21)01206-X
- Cartron G, Bachy E, Tilly H, et al. Randomized phase III trial evaluating subcutaneous rituximab for the first-line treatment of low-tumor burden follicular lymphoma: Results of a LYSA study. *J Clin Oncol*. 2023;41(19):3523-3533. doi:10.1200/JCO.22.02327
- Cook G, Ashcroft J, Fernandez M, et al. Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers. *Front Oncol*. 2023;13:1063144. doi:10.3389/fonc.2023.1063144
- Dall'Olio FG, Marabelle A, Caramella C, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. *Nat Rev Clin Oncol*. 2022;19(2):75-90. doi:10.1038/s41571-021-00564-3
- Davis JA, Youngberg H, Gaffney K, Duco M, Hashmi H. 'Fast but not so Furious': Short observation time after subcutaneous daratumumab administration is both a safe and cost-effective strategy. *Clin Lymphoma Myeloma Leuk*. 2022;22(8):e680-e684. doi:10.1016/j.clml.2022.03.006
- El Hajj J, Reddy S, Verma N, Huang EH, Kazmi SM. Immune checkpoint inhibitors in pMMR/MSS colorectal cancer. *J Gastrointest Cancer*. 2023;54(4):1017-1030. doi:10.1007/s12029-023-00927-2
- Fletcher K, Johnson DB. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. *J Immunother Cancer*. 2024;12(7):e008591. doi:10.1136/jitc-2023-008591
- Fortner B, Viale PH. Health economic analysis of the burden of infusion reactions on patients, caregivers, and providers. *Oncology*. 2009;23(2 Suppl 1):31-36.
- George S, Bournon MT, Chaco MR, et al. Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T. *J Clin Oncol*. 2024;42:LBA360. doi:10.1200/JCO.2024.42.4\_suppl.LBA360
- Heo YA, Syed YY. Subcutaneous trastuzumab: A review in HER2-positive breast cancer. *Target Oncol*. 2019;14(6):749-758. doi:10.1007/s11523-019-00684-y
- Inoue Y. Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration? *Transl Lung Cancer Res*. 2024;13(4):947-951. doi:10.21037/tlcr-24-63
- Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): A phase 3, open-label, multicentre, randomised trial. *Lancet Oncol*. 2012;13(9):869-878. doi:10.1016/S1470-2045(12)70329-7
- Jacobs CR, Rapoport BL, Cohen GL, et al. Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: Analysis from the KEYNOTE-555 Cohort A in metastatic melanoma. *Cancer Res*. 2021;81(13 Suppl):CT143. doi:10.1158/1538-7445.AM2021-CT143

## Oncologist's Corner: Conversations with Cancer Experts About Novel Delivery Options with Immune Checkpoint Inhibitors



Johnson ML, Braiteh F, Grilley-Olson JE, et al. Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: A phase 1 dose-escalation trial. *JAMA Oncol.* 2019;5(7):999-1007. doi:10.1001/jamaoncol.2019.0836

Keytruda. Prescribing information. Merck, Inc. Published 2025. Accessed April 15, 2025. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/125514s172lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s172lbl.pdf)

Law NLW, Hong LW, Tan SSN, Foo CJ, Lee D, Voon PJ. Barriers and challenges of multidisciplinary teams in oncology management: A scoping review protocol. *BMJ Open.* 2024;14(2):e079559. doi:10.1136/bmjopen-2023-079559

Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: Contribution of basic research and clinical application in cancer immunotherapy. *Immune Netw.* 2022;22(1):e2. doi:10.4110/in.2022.22.e2

Lonardi S, Lugowska I, Jackson CGCA, et al. CheckMate-8KX: phase I/II multi-tumor preliminary analyses of a subcutaneous formulation of nivolumab (+/- rHuPH20). *J Clin Oncol.* 2021;39(Suppl 15):2575.

Lonardi S, Bennett BM, Dixon M. 739P - Patient preference for subcutaneous nivolumab with/without recombinant human hyaluronidase PH20 (rHuPH20) vs. intravenous nivolumab: An exploratory subanalysis of a phase I/II pharmacokinetic multi-tumor study. *Ann Oncol.* 2022;33(Suppl 7):S331-S355.

Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematol.* 2020;7(5):e370-e380. doi:10.1016/S2352-3026(20)30070-3

McCloskey C, Ortega MT, Nair S, Garcia MJ, Manevy F. A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting. *Pharmacoecon Open.* 2023;7(1):3-36. doi:10.1007/s41669-022-00361-3

Merck. Merck announces phase 3 trial of subcutaneous pembrolizumab with berahyaluronidase alfa met primary endpoints. Published November 19, 2024. Accessed December 1, 2024. <https://www.merck.com/news/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase-alfa-met-primary-endpoints/>

Merck Sharp & Dohme LLC. A study of subcutaneous (SC) pembrolizumab coformulated with hyaluronidase (MK-3475A) vs intravenous pembrolizumab in adult participants with metastatic non-small cell lung cancer (NSCLC) (MK-3475A-D77). Last Updated November 27, 2024. Accessed December 1, 2024. <https://clinicaltrials.gov/study/NCT05722015>

National Comprehensive Cancer Network Guidelines. Hepatocellular Carcinoma. Version 1.2025. Published March 20, 2025. Accessed July 7, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/hcc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf)

National Comprehensive Cancer Network Guidelines. Management of Immunotherapy-Related Toxicities. Version 1.2025. Published December 20, 2024. Accessed July 7, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/immunotherapy.pdf](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf)


National Comprehensive Cancer Network Guidelines. Melanoma: Cutaneous. Version 2.2025. Published January 28, 2025. Accessed July 7, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/cutaneous\\_melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf)

National Comprehensive Cancer Network Guidelines. Non-Small Cell Lung Cancer. Version 6.2025. Published July 2, 2025. Accessed July 7, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf)

National Comprehensive Cancer Network Guidelines. Small Cell Lung Cancer. Version 4.2025. Published January 13, 2025. Accessed July 7, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/sclc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf)

O'Meara CH, Jafri Z, Khachigian LM. Immune checkpoint inhibitors, small-molecule immunotherapies and the emerging role of neutrophil extracellular traps in therapeutic strategies for head and neck cancer. *Int J Mol Sci.* 2023;24(14):11695. doi:10.3390/ijms241411695

## Oncologist's Corner: Conversations with Cancer Experts About Novel Delivery Options with Immune Checkpoint Inhibitors



Opdivo. Prescribing information. Bristol-Myers Squibb Company. Published 2024. Accessed April 15, 2025. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/125554s128lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s128lbl.pdf)

Pivot X, Gligorov J, Müller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study. *Lancet Oncol.* 2013;14(10):962-970. doi:10.1016/S1470-2045(13)70383-8

Roswell Park Comprehensive Cancer Center. Subcutaneous nivolumab as effective as IV for renal cell carcinoma – with much faster treatment time. Published January 27, 2024. Accessed December 1, 2024. <https://www.roswellpark.org/newsroom/202401-subcutaneous-nivolumab-effective-iv-renal-cell-carcinoma-much-faster-treatment-time>

Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. *Curr Oncol.* 2022;29(5):3044-3060. doi:10.3390/curroncol29050247

Smith GL, Lopez-Olivo MA, Advani PG, et al. Financial burdens of cancer treatment: A systematic review of risk factors and outcomes. *J Natl Compr Canc Netw.* 2019;17(10):1184-1192. doi:10.6004/jnccn.2019.7305

Soefje SA, Carpenter C, Carlson K, et al. Clinical administration characteristics of subcutaneous and intravenous administration of daratumumab in patients with multiple myeloma at Mayo Clinic infusion centers. *JCO Oncol Pract.* 2023;19(4):e542-e549. doi:10.1200/OP.22.00421

Soukup T, Lamb BW, Morbi A, et al. Cancer multidisciplinary team meetings: Impact of logistical challenges on communication and decision-making. *BJS Open.* 2022;6(4):zrac093. doi:10.1093/bjsopen/zrac093

Tan AR, Im SA, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): A randomised, open-label, multicentre, non-inferiority, phase 3 study. *Lancet Oncol.* 2021;22(1):85-97. doi:10.1016/S1470-2045(20)30536-2

Tang S, Qin C, Hu H, et al. Immune checkpoint inhibitors in non-small cell lung cancer: Progress, challenges, and prospects. *Cells.* 2022;11(3):320. doi:10.3390/cells11030320

Tecentriq. Prescribing information. Genentech, Inc. Published 2024. Accessed April 15, 2025. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/761034s053lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf)

Thana M, Wood L. Immune checkpoint inhibitors in genitourinary malignancies. *Curr Oncol.* 2020;27(Suppl 2):S69-S77. doi:10.3747/co.27.5121

U.S. Food & Drug Administration. FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection. Published September 12, 2024. Accessed November 29, 2024. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-and-hyaluronidase-tqjs-subcutaneous-injection>

Waller CF, Möbius J, Fuentes-Albuero A. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. *Br J Cancer.* 2021;124(8):1346-1352. doi:10.1038/s41416-020-01255-z

Yelvington BJ. Subcutaneous rituximab in follicular lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. *J Adv Pract Oncol.* 2018;9(5):530-534.